T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results
Received record quarterly sepsis test panel orders and strengthened balance sheet LEXINGTON, Mass., July 12,…
Received record quarterly sepsis test panel orders and strengthened balance sheet LEXINGTON, Mass., July 12,…
Received record quarterly sepsis test panel orders and strengthened balance sheet LEXINGTON, Mass., July 12,…
Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments…
Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments…
MARLBOROUGH, Mass., July 12, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The…
MARLBOROUGH, Mass., July 12, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The…
CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) — Apnimed, Inc., a clinical-stage pharmaceutical company focused…
CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) — Apnimed, Inc., a clinical-stage pharmaceutical company focused…
SHANGHAI, China and PRINCETON, N.J., July 12, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a…
SHANGHAI, China and PRINCETON, N.J., July 12, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a…
QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023…
QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023…
AUSTIN, Texas, July 12, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing…
AUSTIN, Texas, July 12, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing…
Dr. Adrienne Graves to join Board of Directors BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE)…
Dr. Adrienne Graves to join Board of Directors BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE)…
RJ Tesi MD, CEO of INmune Bio, to Present Opening Keynote on Drug Development Strategies…
RJ Tesi MD, CEO of INmune Bio, to Present Opening Keynote on Drug Development Strategies…
Slynd® Slynd® is now reimbursed for 100% of Quebec women to whom it is indicated….
Slynd® Slynd® is now reimbursed for 100% of Quebec women to whom it is indicated….